Author: TORREY PINES INVESTMENT

Posted Date:

May 25, 2026

Brenig Therapeutics to Present Hybrid AI Drug Discovery Platform at Keystone Symposia Computational Advances in Drug Discovery

TORREY PINES INVESTMENT

May 25, 2026
Brenig Therapeutics to Present Phase 1 Data for BT-267 at the American Academy of Neurology (AAN) 2026 Annual Meeting

TORREY PINES INVESTMENT

May 23, 2026
Brenig Therapeutics Announces Oral Presentation of Phase 1 Data for BT-267 at AD/PD™ 2026, and Provides Updates on BT-409, its NLRP3 Inhibitor Program

TORREY PINES INVESTMENT

May 20, 2026
Mwyngil Therapeutics Announces Updates on NLRP3 Portfolio

TORREY PINES INVESTMENT

February 2, 2026
Mair Therapeutics Announces Scientific Collaboration with Radboud University to Advance TMEM175 Agonists for Parkinson’s Disease

TORREY PINES INVESTMENT

January 27, 2026